Early post-transplant immune monitoring can predict long-term kidney graft survival: Soluble CD30 levels, anti-HLA antibodies and IgA-anti-Fab autoantibodies

Human Immunology

Volumn 75, Issue 1, 2014, Pages 47-58

  Amirzargar, Mohammad Ali ^a   Amirzargar, Aliakbar ^b   Basiri, Abbas ^c   Hajilooi, Mehrdad ^a   Roshanaei, Ghodratollah ^d   Rajabi, Gholamreza ^a   Mohammadiazar, Sina ^a   Solgi, Ghasem ^a  

^a HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD30 ANTIGEN; CREATININE; CYCLOSPORIN A; HLA ANTIBODY; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IGA FAB AUTOANTIBODY; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; MEPREDNISONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LABORATORY TEST; LIVING DONOR; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE INFECTION; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RISK FACTOR; UNRELATED DONORS;

ADULT; ANTIGENS, CD30; AUTOANTIBODIES; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY ANTIGENS; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN FAB FRAGMENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MONITORING, IMMUNOLOGIC;

EID: 84890210092     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2013.09.010     Document Type: Article

References (40)

1. Cravedi P., Heeger P.S. Immunologic monitoring in transplantation revisited. Curr Opin Organ Transplant 2012, 17(1):26-32.
2. Mannon R.B. Immune monitoring and biomarkers to predict chronic allograft dysfunction. Kidney Int Suppl 2010, 119:S59-S65.
3. Langan L.L., Park L.P., Hughes T.L., Irish A., Luxton G., Witt C.S., et al. Post-transplant HLA class II antibodies and high soluble CD30 levels are independently associated with poor kidney graft survival. Am J Transplant 2007, 7(4):847-856.
4. Ho J., Wiebe C., Gibson I.W., Rush D.N., Nickerson P.W. Immune monitoring of kidney allografts. Am J Kidney Dis 2012, 60(4):629-640.
5. Langan L.L., D'Orsogna L., Park L.P., Hughes T.L., Irish A., Luxton G., et al. HLA antibodies and soluble CD30 are associated with poor renal graft outcome: updated results of a single-center cross-sectional study. Clin Transpl 2006, 219-225.
6. Rodríguez L.M., París S.C., Arbeláez M., Cotes J.M., Süsal C., Torres Y., et al. Kidney graft recipients with pretransplantation HLA CLASS I antibodies and high soluble CD30are at high risk for graft loss. Hum Immunol 2007, 68:652-660.
7. Solgi G., Furst D., Mytilineos J., Pourmand G., Amirzargar A.A. Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA. Transpl Immunol 2012, 26(2-3):81-87.
8. Solgi G., Amirzagar A.A., Pourmand G., Mehrsai A.R., Taherimahmoudi M., Baradaran N., et al. TH1/TH2 cytokines and soluble CD30 levels in kidney allograft patients with donor bone marrow cell infusion. Transplant Proc 2009, 41(7):2800-2804.
9. Süsal C., Opelz G. Kidney graft failure and presensitization against HLA class I and class II antigens. Transplantation 2002, 73:1269-1273.
10. Süsal C., Pelzl S., Dohler B., Opelz G. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 2002, 13:1650.
11. Slavcev A., Lacha J., Honsova E., Sajdlova H., Lodererova A., Vitko S., et al. Soluble CD30 and HLA antibodies as potential risk factors for kidney transplant rejection. Transplant Immunol 2005, 14:117-121.
12. Cinti P., Pretagostini R., Arpino A., Tamburro M.L., Mengasini S., Lattanzi R., et al. Evaluation of pretransplant immunologic status in kidney-transplant recipients by panel reactive antibody and soluble CD30 determinations. Transplantation 2005, 79:1154.
13. Pelzl S., Opelz G., Wiesel M., Schnulle P., Schonemann C., Dohler B., et al. Soluble CD30 as a predictor of kidney graft outcome. Transplantation 2002, 73:3.
14. Mizutani K., Terasaki P., Rosen A., et al. Serial 10year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant 2005, 5:2265.
15. Mizutani K., Terasaki P., Hamdani E., et al. The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am J Transplant 2007, 7:1027.
16. Mizutani K., Shibata L., Ozawa M., et al. Detection of HLA and MICA antibodies before kidney graft failure. Clin Transpl 2006, 7:255.
17. Kinukawa T., Kato M., Terasaki P.I., et al. Retrospective antibody analysis of thirty patients with kidney graft failure. Clin Transpl 2006, 7:291.
18. van den Berg-Loonen E.M., Terasaki P., Kohanof S., et al. Longitudinal testing of seventy-six renal allograft patients for HLA antibodies: maastricht experience. Clin Transpl 2006, 7:305.
19. Süsal C., Dohler B., Opelz G. The collaborative transplant study. Graft-protective role of high pretransplantation IgA-anti-Fab autoantibodies: confirmatory evidence obtained in more than 4000 kidney transplants. Transplantation 2000, 69:1337.
20. Doran T.J., Süsal C., Opelz G., Geczy A.F. IgA class antibodies and flow cytometric cross-matching in renal transplantation. Transplantation 1999, 67:309.
21. Süsal C., Dorr C., Groth J., May G., Opelz G. Pretransplant serum IgA concentration and IgA-anti-Fab autoantibody activity as prognostic indicators of kidney graft survival. Transplant Int 1994, 7:S586.
22. Süsal C., Wiesel M., Schonemann C., Groth J., Carl S., Staehler G., et al. Presensitization and HLA match influence the predictive power of pretransplant serum IgA and IgA-anti-Fab autoantibodies in kidney graft recipients. Transplant Proc 1997, 29:1444.
23. Süsal C., Wiesel M., Staehler G., Groth J., May G., Opelz G. Excellent kidney graft survival in patients with high pretransplant serum IgA concentrations and IgA-anti-Fab autoantibody activity. Transplant Proc 1995, 27:1072.
24. Pavlova Y., Viklicky O., Slatinska J., Bürgelova M., Süsal C., Skibova J., et al. Soluble CD30 and Hepatocyte growth factor as predictive markers of antibody-mediated rejection of the kidney allograft. Transpl Immunol 2011, 25(1):72-76.
25. Pelzl S., Opelz G., Daniel V., Wiesel M., Süsal C. Evaluation of post-transplantationation soluble CD30 for diagnosis of acute renal allograft rejection. Transplantation 2003, 75:421.
26. Romagnani S., Del Prete G., Maggi E., Chilosi M., Caligaris-Cappio F., Pizzolo G. CD30 and type 2 T helper (Th2) responses. J Leukoc Biol 1995 May, 57(5):726-730.
27. Tarkowski M. Expression and a role of CD30 in regulation of T-cell activity. Curr Opin Hematol 2003, 10(4):267-271.
28. Rajakariar R., Jivanji N., Varagunam M., Rafiq M., Gupta A., Sheaff M., et al. High pretransplant soluble CD30 levels are predictive of the grade of rejection. Am J Transplant 2005, 5:1922-1925.
29. Martinez O.M., Villanueva J., Abtahi S., Beatty P.R., Esquivel C.O., Krams S.M. CD30 expression identifies a functional alloreactive human T-lymphocyte subset. Transplantation 1998, 65(9):1240-1247.
30. Pellegrini P., Berghella A.M., Contasta I., Adorno D. CD30 antigen: not a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 response. Transpl Immunol 2003, 12:49-61.
31. Loupy A., Hill G.S., Jordan S.C. The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol 2012, 8(6):348-357.
32. Terasaki P.I., Ozawa M., Castro R. 4year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 2007, 7:408-415.
33. Lee P.C., Zhu L., Terasaki P.I., Everly M.J. HLA-specific antibodies developed in the first year post-transplant are predictive of chronic rejection and renal graft loss. Transplantation 2009, 88(4):568-574.
34. Süsal C., Opelz G. Good kidney transplant outcome in recipients with presensitization against HLA class II but not HLA class I. Hum Immunol 2004, 65:810.
35. Chaudhuri A., Ozawa M., Everly M.J., Ettenger R., Dharnidharka V., Benfield M., et al. The clinical impact of humoral immunity in pediatric renal transplantation. J Am Soc Nephrol 2013, 24(4):655-664. Epub 2013 Feb 28. 10.1681/ASN.2012070663.
36. Terasaki P.I., Ozawa M. Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2year prospective trial. Transplantation 2005, 80:1194-1197.
37. Ntokou I.S., Iniotaki A.G., Kontou E.N., Darema M.N., Apostolaki M.D., Kostakis A.G., et al. Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules. Transpl Int 2011, 24(11):1084-1093.
38. Lachmann N., Terasaki P.I., Schonemann C. Donor-specific HLA antibodies in chronic renal allograft rejection: a prospective trial with a 4year follow-up. Clin Transpl 2006, 171.
39. Gerbase-DeLima M., Campos E.F., Tedesco-Silva H., et al. Anti-HLA class II antibodies and chronic allograft nephropathy. Clin Transpl 2006, (6):201.
40. Kim M.S., Kim Y.S., Kim S.I., Lee J.W., Moon J.I., Park K. Pretransplant serum IgA concentration and IgA-anti-Fab autoantibody activity in living donor renal transplant recipients: a pilot study. Transplant Proc 1998, 30(7):2977-2978.